Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Assets Average (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Assets Average for 6 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 41.33% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 41.33% increase, with the full-year FY2025 number at $1.4 billion, up 75.11% from a year prior.
  • Assets Average was $1.4 billion for Q4 2025 at Kymera Therapeutics, up from $1.1 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.4 billion in Q4 2025 to a low of $449.5 million in Q2 2021.
  • A 5-year average of $738.6 million and a median of $614.7 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: decreased 9.14% in 2023, then surged 78.42% in 2024.
  • Kymera Therapeutics' Assets Average stood at $624.2 million in 2021, then fell by 0.54% to $620.8 million in 2022, then decreased by 9.14% to $564.1 million in 2023, then soared by 78.42% to $1.0 billion in 2024, then soared by 41.33% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Assets Average are $1.4 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025).